Compare Stocks: AAPG, CGON, ERAS, and MIRM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$17.63 +4.9%	$18.21	$16.23 ▼ $41.40	$1.65B	0.08	6,857 shs	9,098 shs
CGON CG Oncology	$74.17 -0.6%	$73.54	$28.33 ▼ $80.97	$6.57B	0.24	1.11 million shs	129,255 shs
ERAS Erasca	$16.13 -1.5%	$18.32	$1.40 ▼ $24.28	$5.64B	0.64	6.01 million shs	1.16 million shs
MIRM Mirum Pharmaceuticals	$100.36 +0.5%	$109.88	$63.23 ▼ $130.00	$6.52B	0.49	855,808 shs	167,068 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+3.57%	-0.53%	0.00%	-8.04%	-59.80%
CGON CG Oncology	-1.67%	-4.88%	+7.87%	+32.98%	+171.63%
ERAS Erasca	-2.33%	-14.52%	-8.24%	+23.36%	+923.13%
MIRM Mirum Pharmaceuticals	+1.52%	+1.34%	-4.55%	+7.94%	+34.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$17.63 +4.9%	$18.21	$16.23 ▼ $41.40	$1.65B	0.08	6,857 shs	9,098 shs
CGON CG Oncology	$74.17 -0.6%	$73.54	$28.33 ▼ $80.97	$6.57B	0.24	1.11 million shs	129,255 shs
ERAS Erasca	$16.13 -1.5%	$18.32	$1.40 ▼ $24.28	$5.64B	0.64	6.01 million shs	1.16 million shs
MIRM Mirum Pharmaceuticals	$100.36 +0.5%	$109.88	$63.23 ▼ $130.00	$6.52B	0.49	855,808 shs	167,068 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+3.57%	-0.53%	0.00%	-8.04%	-59.80%
CGON CG Oncology	-1.67%	-4.88%	+7.87%	+32.98%	+171.63%
ERAS Erasca	-2.33%	-14.52%	-8.24%	+23.36%	+923.13%
MIRM Mirum Pharmaceuticals	+1.52%	+1.34%	-4.55%	+7.94%	+34.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.20	Buy	$46.43	176.20% Upside
CGON CG Oncology	2.77	Moderate Buy	$83.18	11.52% Upside
ERAS Erasca	2.64	Moderate Buy	$22.09	34.95% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$137.31	37.55% Upside

Current Analyst Ratings Breakdown

Latest AAPG, CGON, ERAS, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	MIRM Mirum Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$137.00
8/27/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/27/2026	MIRM Mirum Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$137.00
8/21/2026	AAPG Ascentage Pharma Group International	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$48.00
8/14/2026	ERAS Erasca	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00
8/13/2026	ERAS Erasca	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $21.00
8/12/2026	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $22.00
8/7/2026	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$81.00 ➝ $79.00
8/7/2026	CGON CG Oncology	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $85.00
8/7/2026	CGON CG Oncology	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$82.00 ➝ $85.00
8/6/2026	MIRM Mirum Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$82.10M	19.12	N/A	N/A	$0.89 per share	18.89
CGON CG Oncology	$4.04M	1,636.55	N/A	N/A	$11.61 per share	6.42
ERAS Erasca	N/A	N/A	N/A	N/A	$1.03 per share	N/A
MIRM Mirum Pharmaceuticals	$521.31M	12.43	$0.05 per share	1,929.03	($0.16) per share	-623.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$177.71M	N/A	N/A	840.50	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	11/11/2026 (Estimated)
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)

Latest AAPG, CGON, ERAS, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2026	H1 2026	AAPG Ascentage Pharma Group International	N/A	-$0.65	N/A	-$0.6450	N/A	$22.24 million
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	1.09	1.22	1.18
CGON CG Oncology	N/A	22.22	22.20
ERAS Erasca	N/A	8.29	8.29
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
CGON CG Oncology	26.56%
ERAS Erasca	67.78%
MIRM Mirum Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
CGON CG Oncology	4.80%
ERAS Erasca	14.20%
MIRM Mirum Pharmaceuticals	8.32%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	93.40 million	N/A	N/A
CGON CG Oncology	61	88.64 million	84.39 million	Optionable
ERAS Erasca	120	349.76 million	300.10 million	Optionable
MIRM Mirum Pharmaceuticals	140	64.93 million	59.53 million	Optionable

AAPG, CGON, ERAS, and MIRM Headlines

Recent News About These Companies

Mirum sets Sept. investor conference schedule

September 2 at 7:28 PM | msn.com

Wellington Management Group LLP Sells 24,822 Shares of Mirum Pharmaceuticals, Inc. $MIRM

September 1 at 5:12 AM | marketbeat.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 1 at 4:13 AM | marketbeat.com

Hsbc Holdings PLC Purchases Shares of 12,031 Mirum Pharmaceuticals, Inc. $MIRM

September 1 at 3:59 AM | marketbeat.com

Mirum Pharmaceuticals, Inc. $MIRM Shares Bought by Alyeska Investment Group L.P.

September 1 at 3:12 AM | marketbeat.com

37,183 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by Man Group plc

August 31 at 5:12 AM | marketbeat.com

159,231 Shares in Mirum Pharmaceuticals, Inc. $MIRM Bought by Legal & General Group Plc

August 31 at 5:03 AM | marketbeat.com

Mirum Pharmaceuticals, Inc. $MIRM Shares Acquired by Penn Capital Management Company LLC

August 30, 2026 | marketbeat.com

74,750 Shares in Mirum Pharmaceuticals, Inc. $MIRM Bought by The Manufacturers Life Insurance Company

August 30, 2026 | marketbeat.com

Toth Financial Advisory Corp Makes New Investment in Mirum Pharmaceuticals, Inc. $MIRM

August 29, 2026 | marketbeat.com

Jefferies Financial Group Inc. Takes $4.60 Million Position in Mirum Pharmaceuticals, Inc. $MIRM

August 29, 2026 | marketbeat.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Upgraded to "Hold" at Wall Street Zen

August 29, 2026 | americanbankingnews.com

Citizens Jmp Reiterates Market Outperform Rating for Mirum Pharmaceuticals (NASDAQ:MIRM)

August 29, 2026 | americanbankingnews.com

Wall Street Zen Upgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Hold

August 29, 2026 | marketbeat.com

Algert Global LLC Invests $3.94 Million in Mirum Pharmaceuticals, Inc. $MIRM

August 28, 2026 | marketbeat.com

Mirum Pharmaceuticals' (MIRM) Market Outperform Rating Reiterated at Citizens Jmp

August 27, 2026 | marketbeat.com

415,641 Shares in Mirum Pharmaceuticals, Inc. $MIRM Bought by Boone Capital Management LLC

August 27, 2026 | marketbeat.com

Trails Edge Capital Partners LP Buys New Stake in Mirum Pharmaceuticals, Inc. $MIRM

August 26, 2026 | marketbeat.com

Jupiter Topco LLC Acquires Shares of 5,909,184 Mirum Pharmaceuticals, Inc. $MIRM

August 26, 2026 | marketbeat.com

PDT Partners LLC Acquires New Stake in Mirum Pharmaceuticals, Inc. $MIRM

August 26, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $78.43 Million in Mirum Pharmaceuticals, Inc. $MIRM

August 26, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG, CGON, ERAS, and MIRM Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$17.63 +0.82 (+4.85%)

As of 02:26 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

CG Oncology NASDAQ:CGON

$74.17 -0.42 (-0.56%)

As of 02:44 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Erasca NASDAQ:ERAS

$16.13 -0.24 (-1.47%)

As of 02:46 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$100.36 +0.53 (+0.53%)

As of 02:43 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AAPG, CGON, ERAS, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AAPG, CGON, ERAS, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AAPG, CGON, ERAS, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG, CGON, ERAS, and MIRM Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

CG Oncology NASDAQ:CGON

Erasca NASDAQ:ERAS

Mirum Pharmaceuticals NASDAQ:MIRM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AAPG, CGON, ERAS, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AAPG, CGON, ERAS, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AAPG, CGON, ERAS, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG, CGON, ERAS, and MIRM Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

CG Oncology NASDAQ:CGON

Erasca NASDAQ:ERAS

Mirum Pharmaceuticals NASDAQ:MIRM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools